An increased likelihood of metastatic relapse at a distant site over a relatively short period of time, as well as increased levels of cell proliferation have been associated with triple-negative and human epidermal growth factor receptor 2 (HER2) breast cancers, when compared to other subtypes, indicative of their aggressive clinical course [40]. This evidence concerns the gene ERBB2 and breast carcinoma.